Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, First in Human (FiH) Trial of Apta-1 for the Treatment of Sepsis

Trial Profile

A Phase I, First in Human (FiH) Trial of Apta-1 for the Treatment of Sepsis

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apta 1 (Primary)
  • Indications Sepsis
  • Focus Adverse reactions; First in man
  • Sponsors Aptahem
  • Most Recent Events

    • 08 Feb 2019 According to an Aptahem media release, the delivery of its drug product will be delayed due to some technical difficulties encountered during the contract manufacturer's production. As a consequence, the company anticipates commencement of the planned clinical study for Apta-1 will be delayed.
    • 10 Oct 2018 According to an Aptahem media release, this trial is expected to start in the third quarter of 2019.
    • 27 Jun 2018 According to an Aptahem media release, YA II PN Ltd will provide the funds for this phase 1 first in man study.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top